APC is altered in 2.56% of ependymoma patients [2].

APC is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains APC status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CTDNEP1 is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains CTDNEP1 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CTNNB1 is altered in 1.28% of ependymoma patients [2].

CTNNB1 is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains CTNNB1 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

DDX3X is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

EGFR is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 0 are open and 1 is closed. Of the trial that contains EGFR status and ependymoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ERBB2 is an inclusion eligibility criterion in 2 clinical trials for ependymoma, of which 0 are open and 2 are closed. Of the trials that contain ERBB2 status and ependymoma as inclusion criteria, 2 are phase 1/phase 2 (0 open) [3].

ERBB4 is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB4 status and ependymoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

GLI2 is altered in 2.04% of ependymoma patients [2].

GLI2 is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains GLI2 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

H3F3A is an inclusion eligibility criterion in 3 clinical trials for ependymoma, of which 3 are open and 0 are closed. Of the trials that contain H3F3A status and ependymoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].

IDH1 is an inclusion eligibility criterion in 2 clinical trials for ependymoma, of which 2 are open and 0 are closed. Of the trials that contain IDH1 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

IDH2 is an inclusion eligibility criterion in 2 clinical trials for ependymoma, of which 2 are open and 0 are closed. Of the trials that contain IDH2 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

KDM6A is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains KDM6A status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

KMT2C is altered in 4.44% of ependymoma patients [2].

KMT2C is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2C status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

KMT2D is altered in 9.46% of ependymoma patients [2].

KMT2D is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

LRP1B is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains LRP1B status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MSH2 is altered in 2.7% of ependymoma patients [2].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MSH6 is altered in 1.35% of ependymoma patients [2].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYC is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYCL is altered in 1.35% of ependymoma patients [2].

MYCL is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains MYCL status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYCN is altered in 5.41% of ependymoma patients [2].

MYCN is an inclusion eligibility criterion in 3 clinical trials for ependymoma, of which 3 are open and 0 are closed. Of the trials that contain MYCN status and ependymoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is no phase specified (1 open) [3].

OTX2 is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains OTX2 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PPM1D is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains PPM1D status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PTCH1 is altered in 1.35% of ependymoma patients [2].

PTCH1 is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PTEN is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PVT1 is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains PVT1 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RELA is altered in 13.16% of ependymoma patients [2].

RELA is an inclusion eligibility criterion in 2 clinical trials for ependymoma, of which 1 is open and 1 is closed. Of the trials that contain RELA status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [3].

SHH is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains SHH status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCA4 is altered in 1.35% of ependymoma patients [2].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SMO is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SNCAIP is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains SNCAIP status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SUFU is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains SUFU status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TERT is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains TERT status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 is altered in 2.56% of ependymoma patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

YAP1 is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains YAP1 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ZMYM3 is an inclusion eligibility criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains ZMYM3 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [3].